Cover Image
市場調查報告書

老年癡呆症的治療、診斷:全球市場

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

出版商 BCC Research 商品編碼 105600
出版日期 內容資訊 英文 144 pages
訂單完成後即時交付
價格
Back to Top
老年癡呆症的治療、診斷:全球市場 Alzheimer's Disease Therapeutics and Diagnostics: Global Markets
出版日期: 2016年03月31日 內容資訊: 英文 144 pages
簡介

全球老年癡呆症治療、診斷市場,預計從2015到2020年以7.1%的年複合成長率發展,從2015年的44億美元到2020年達到62億美元以上。

本報告提供老年癡呆症的治療及診斷技術的全球市場調查,市場概要,市場趨勢 (包含資料,年複合成長率預測的) 分析,正在開發的計劃的檢討與市場機會的定量化,市場區隔的經濟環境,技術的說明,課題及應用,及主要企業簡介等彙整,為您概述為以下內容。

第1章 簡介

第2章 摘要

第3章 概要

  • 老年癡呆症:定義、市場結構
  • 老年癡呆症的病理學
  • 老年癡呆症的病因
  • 老年癡呆症的流行病學
  • 老年癡呆症的診斷、治療

第4章 法規情形

  • 美國食品藥物管理局
  • 歐洲藥品管理局

第5章 全球市場

  • 簡介
  • 市場動態
  • 老年癡呆症的治療、診斷的全球市場

第6章 北美的老年癡呆症治療、診斷市場

  • 北美市場

第7章 歐洲的老年癡呆症治療、診斷市場

  • 歐洲市場

第8章 亞太地區的老年癡呆症治療、診斷市場

  • 亞太地區市場

第9章 開發平台分析

  • 老年癡呆症的開發平台(管線)情形
  • 老年癡呆症的開發平台(管線):臨床階段
  • 老年癡呆症的開發平台(管線):治療焦點
  • 老年癡呆症的開發平台(管線):各病期
  • 老年癡呆症的開發平台(管線):作用機制
  • 臨床實驗主要的AB為基礎的治療

第10章 搭配診斷

  • 簡介
  • 老年癡呆症的搭配診斷影像診斷

第11章 企業簡介

  • AB SCIENCE
  • ABBVIE INC.
  • AC IMMUNE SA
  • ALLERGAN PLC
  • AFFIRIS AG
  • AMARANTUS BIOSCIENCE HOLDINGS
  • ANAVEX LIFE SCIENCES
  • ASTRAZENECA
  • AVID RADIOPHARMACEUTICALS
  • AXON NEUROSCIENCE
  • AXOVANT SCIENCES
  • BIOGEN
  • BOEHRINGER INGELHEIM
  • DAIICHI SANKYO CO
  • DIAGENIC
  • EISAI
  • ELI LILLY
  • F. HOFFMANN LA ROCHE AG
  • GE HEALTHCARE
  • H. LUNDBECK A/S
  • JANSSEN PHARMACEUTICALS
  • MERCK & CO
  • NAVIDEA BIOPHARMACEUTICALS
  • NEUROTRAX CORP.
  • NOVARTIS PHARMA SERVICES AG
  • ONO PHARMACEUTICAL CO.
  • OTSUKA PHARMACEUTICALS
  • PFIZER INC
  • PIRAMAL IMAGING GMBH
  • TAURX THERAPEUTICS

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHM062C

REPORT HIGHLIGHTS

The global market for AD therapeutics and diagnostics by region should reach over $6.2 billion by 2020 from $4.4 billion in 2015, at a compound annual growth rate (CAGR) of 7.1% from 2015 to 2020.

This report provides:

  • An overview of the global market for Alzheimer's disease therapeutic and diagnostic technologies
  • Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020
  • Review of programs in development and quantification of market opportunities
  • Discussion of the market segments' economic environment, technological descriptions and issues, and applications
  • Projections of usage in the major primary and secondary disease application areas
  • Profiles of major players in the industry

image1

REPORT SCOPE

SCOPE OF THE STUDY

The scope of this study encompasses the global and regional markets for Alzheimer's therapeutics and diagnostics. These markets are segmented by branded and generic drugs, mechanism of action, such as acetylcholine inhibitors (AChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonists, a combination drug of donepezil and memantine, tau aggregation inhibitors (TAI) and amyloid-beta (AΒ) vaccines. Drugs are also segmented by the stage of Alzheimer's disease they treat: mild to moderate, severe and prodromal.

BCC Research analyzed each market and its applications, regulatory environment, assistive technologies, market projections and market share. Issues discussed include the major drug profiles, clinical groundwork, technological features and trends. The regional markets for AD therapeutics and diagnostics include selected markets in the U.S., Canada, the U.K., France, Germany, Italy, Spain, Japan, China and India. These markets are grouped as North America, Europe and Asia-Pacific. The rest of the world markets are not addressed because of their economic insignificance with respect to this report.

ANALYST'S CREDENTIALS

This report was authored by Ufuk Ezer. Ezer holds a bachelor's degree in bioengineering and a master's degree in biotechnology, bioprocessing and business management. The analyst possesses extensive pharmaceutical research and development experience through participating projects in various international institutions and organizations. Ezer has been granted scholarships and awards during his post-study works in countries such as Japan and Panama based on the high quality of his work and excellence in the fields of research. Previous analyst reports include BIO136A G-protein Couples Receptor (GPCR) Targeting: Technologies and Global Markets and HLC181A Diagnostics and Therapeutics for Autism Spectrum Disorders: Global Markets.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • INFORMATION SOURCES
  • METHODOLOGY
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • SUMMARY TABLE GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, 2014-2020 ($ MILLIONS)

CHAPTER 3 OVERVIEW

  • ALZHEIMER'S DISEASE: DEFINITION AND MARKET STRUCTURE
  • FIGURE 1 CHANGE IN ALZHEIMER'S POPULATION AND COST OF CARE IN THE U.S., 2015-2030 (MILLIONS/$ BILLIONS)
  • ALZHEIMER'S DISEASE PATHOPHYSIOLOGY
    • AD AND AMYLOID CASCADE
    • AD AND TAUOPATHY
    • AD AND NEUROTRANSMITTER SYSTEMS
  • ALZHEIMER'S DISEASE ETIOLOGY
    • GENETIC FACTORS
      • Early-Onset Familial AD
      • Late-Onset Sporadic AD
    • NON-GENETIC FACTORS
  • ALZHEIMER'S DISEASE EPIDEMIOLOGY
    • AGE OF ONSET
    • INCIDENCE, PREVALENCE AND MORTALITY
      • Incidence of AD
      • Prevalence of AD
      • TABLE 1 PREVALENCE RATES OF ALZHEIMER'S BY REGION, 2014 (%)
      • FIGURE 2 GLOBAL PREVALENCE RATES OF ALZHEIMER'S BY AGE GROUP AND REGION (%)
      • TABLE 2 GLOBAL ALZHEIMER'S POPULATION BY AGE GROUP AND REGION, 2014 (MILLIONS)
      • FIGURE 3 GLOBAL ALZHEIMER'S POPULATION BY AGE GROUP AND REGION, 2014 (MILLIONS)
      • Mortality in AD
    • STAGES AND SEVERITY OF AD
      • Stage 1: Asymptomatic AD
      • Stage 2: Very mild AD
      • Stage 3: Mild AD
      • Stage 4: Moderate AD
      • Stage 5: Moderately severe AD
      • Stage 6: Severe decline
      • Stage 7: Very severe AD
    • COMORBIDITIES
    • TABLE 3 PHARMACOLOGICAL TREATMENT OF BPSD OF ALZHEIMER'S
  • DIAGNOSIS AND TREATMENT OF ALZHEIMER'S
    • DIAGNOSIS OF ALZHEIMER'S
      • Cognitive Status Testing
        • ADAS-Cog
        • Computerized Screening Tests
        • TABLE 4 COMPUTERIZED SCREENING TESTS USED IN DETECTING COGNITIVE IMPAIRMENT
      • Genetic Testing
      • Brain Imaging
      • TABLE 5 BRAIN IMAGING TECHNOLOGIES AND APPLICATION IN THE ALZHEIMER'S CONTEXT
      • Lumbar Puncture
    • PHARMACEUTICAL TREATMENT OF AD

CHAPTER 4 REGULATORY LANDSCAPE

  • U.S. FOOD AND DRUG ADMINISTRATION
  • TABLE 6 DIAGNOSTIC IMAGING TRACERS APPROVED BY THE FDA
  • EUROPEAN MEDICINES AGENCY

CHAPTER 5 GLOBAL MARKETS

  • INTRODUCTION
  • MARKET DYNAMICS
    • TOP PLAYERS IN THE GLOBAL MARKET FOR AD THERAPEUTICS
    • TABLE 7 GLOBAL MARKET SHARES OF LEADING COMPANIES IN ALZHEIMER'S THERAPEUTICS, 2020 (%)
    • FIGURE 4 GLOBAL MARKET SHARES OF LEADING COMPANIES IN ALZHEIMER'S THERAPEUTICS, 2020 (%)
  • GLOBAL MARKET FOR AD THERAPEUTICS AND DIAGNOSTICS
    • MARKET BY REGION
    • FIGURE 5 GLOBAL MARKET SHARES OF ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, 2015 (%)
    • TABLE 8 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 6 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, 2014-2020 ($ MILLIONS)
    • MARKET BY APPLICATION SEGMENT
    • TABLE 9 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 7 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION, 2014-2020 ($ MILLIONS)
      • Global Market for AD Therapeutics
        • Global Market for AD Therapeutics by Region
        • TABLE 10 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY REGION, THROUGH 2020 ($ MILLIONS)
        • FIGURE 8 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY REGION, 2014-2020 ($ MILLIONS)
        • Global Market for Branded/Generic AD Therapeutics
        • TABLE 11 GLOBAL MARKET FOR GENERIC/BRANDED ALZHEIMER'S THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
        • FIGURE 9 GLOBAL MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, 2014-2020 ($ MILLIONS)
        • Global Market for AD Therapeutics by Mechanism of Action
        • TABLE 12 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, THROUGH 2020 ($ MILLIONS)
        • FIGURE 10 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, 2014-2020 ($ MILLIONS)
          • Global Market for AChEIs
          • TABLE 13 GLOBAL MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, THROUGH 2020 ($ MILLIONS)
          • FIGURE 11 GLOBAL MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, 2014-2020 ($ MILLIONS)
          • TABLE 14 GLOBAL MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY REGION, THROUGH 2020 ($ MILLIONS)
          • FIGURE 12 GLOBAL MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY REGION, 2014-2020 ($ MILLIONS)
          • Global Market for NMDA Drugs
          • TABLE 15 GLOBAL MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH 2020 ($ MILLIONS)
          • FIGURE 13 GLOBAL MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 ($ MILLIONS)
          • TABLE 16 GLOBAL MARKET FOR NMDA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
          • FIGURE 14 GLOBAL MARKET FOR NMDA DRUGS BY REGION, 2014-2020 ($ MILLIONS)
        • Global Market for Other AD Therapeutics
        • TABLE 17 GLOBAL MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY REGION, THROUGH 2020 ($ MILLIONS)
        • FIGURE 15 GLOBAL MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY REGION, 2014-2020 ($ MILLIONS)
        • Global Market for AD Therapeutics by AD Stage
        • TABLE 18 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, THROUGH 2020 ($ MILLIONS)
        • FIGURE 16 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, 2014-2020 ($ MILLIONS)
      • Global Market for AD Diagnostics
        • Global AD Diagnostics Market by Region
        • TABLE 19 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY REGION, THROUGH 2020 ($ MILLIONS)
        • FIGURE 17 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY REGION, 2014-2020 ($ MILLIONS)
        • Global AD Diagnostics Market by Molecular Target
        • TABLE 20 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, THROUGH 2020 ($ MILLIONS)
        • FIGURE 18 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, 2014-2020 ($ MILLIONS)

CHAPTER 6 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS

  • NORTH AMERICAN MARKET
  • TABLE 21 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, THROUGH 2020 ($ MILLIONS)
  • FIGURE 19 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, 2014-2020 ($ MILLIONS)
    • NORTH AMERICAN MARKET FOR AD THERAPEUTICS BY COUNTRY
    • TABLE 22 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
    • FIGURE 20 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, 2014-2020 ($ MILLIONS)
    • NORTH AMERICAN MARKET FOR BRANDED/GENERIC AD THERAPEUTICS
    • TABLE 23 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
    • FIGURE 21 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, 2014-2020 ($ MILLIONS)
    • NORTH AMERICAN MARKET FOR AD THERAPEUTICS BY MECHANISM OF ACTION
    • TABLE 24 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 22 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, 2014-2020 ($ MILLIONS)
      • North American Market for AChEIs
      • TABLE 25 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, THROUGH 2020 ($ MILLIONS)
      • FIGURE 23 NORTH AMERICAN MARKET FOR BRANDED/GENERIC
      • ACETYLCHOLINESTERASE INHIBITORS, 2014-2020 ($ MILLIONS)
      • TABLE 26 NORTH AMERICAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
      • FIGURE 24 NORTH AMERICAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS MARKET BY COUNTRY, 2014-2020 ($ MILLIONS)
      • North American Market for NMDA Drugs
      • TABLE 27 NORTH AMERICAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH 2020 ($ MILLIONS)
      • FIGURE 25 NORTH AMERICAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 ($ MILLIONS)
      • TABLE 28 NORTH AMERICAN MARKET FOR NMDA DRUGS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
      • FIGURE 26 NORTH AMERICAN MARKET FOR NMDA DRUGS BY COUNTRY, 2014-2020 ($ MILLIONS)
      • North American Market for Other AD Therapeutics
      • TABLE 29 NORTH AMERICAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
      • FIGURE 27 NORTH AMERICAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY COUNTRY, 2014-2020 ($ MILLIONS)
    • NORTH AMERICAN MARKET FOR AD THERAPEUTICS BY AD STAGE
    • TABLE 30 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, THROUGH 2020 ($ MILLIONS)
    • FIGURE 28 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE 2014-2020 ($ MILLIONS)
    • NORTH AMERICAN MARKET FOR AD DIAGNOSTICS BY MOLECULAR TARGET
    • TABLE 31 NORTH AMERICAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, THROUGH 2020 ($ MILLIONS)
    • FIGURE 29 NORTH AMERICAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, 2014-2020 ($ MILLIONS)

CHAPTER 7 EUROPEAN MARKETS FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS

  • EUROPEAN MARKETS
  • TABLE 32 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, THROUGH 2020 ($ MILLIONS)
  • FIGURE 30 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, 2014-2020 ($ MILLIONS)
    • EUROPEAN MARKET FOR AD THERAPEUTICS BY COUNTRY
    • TABLE 33 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
    • FIGURE 31 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, 2014-2020 ($ MILLIONS)
    • EUROPEAN MARKET FOR BRANDED/GENERIC AD THERAPEUTICS
    • TABLE 34 EUROPEAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
    • FIGURE 32 EUROPEAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, 2014-2020 ($ MILLIONS)
    • EUROPEAN MARKET FOR AD THERAPEUTICS BY MECHANISM OF ACTION
    • TABLE 35 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 33 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, 2014-2020 ($ MILLIONS)
      • European Market for AChEIs
      • TABLE 36 EUROPEAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, THROUGH 2020 ($ MILLIONS)
      • FIGURE 34 EUROPEAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, 2014-2020 ($ MILLIONS)
      • TABLE 37 EUROPEAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
      • FIGURE 35 EUROPEAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, 2014-2020 ($ MILLIONS)
      • European Market for NMDA Drugs
      • TABLE 38 EUROPEAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH 2020 ($ MILLIONS)
      • FIGURE 36 EUROPEAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 ($ MILLIONS)
      • TABLE 39 EUROPEAN MARKET FOR NMDA DRUGS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
      • FIGURE 37 EUROPEAN MARKET FOR NMDA DRUGS BY COUNTRY, 2014-2020 ($ MILLIONS)
      • European Markets for Other AD Therapeutics
      • TABLE 40 EUROPEAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
      • FIGURE 38 EUROPEAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
    • EUROPEAN MARKET FOR AD THERAPEUTICS BY AD STAGE
    • TABLE 41 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, THROUGH 2020 ($ MILLIONS)
    • FIGURE 39 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, 2014-2020 ($ MILLIONS)
    • EUROPEAN MARKET FOR AD DIAGNOSTICS
    • TABLE 42 EUROPEAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, THROUGH 2020 ($ MILLIONS)
    • FIGURE 40 EUROPEAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, 2014-2020 ($ MILLIONS)

CHAPTER 8 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS

  • ASIA-PACIFIC MARKET
  • TABLE 43 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, THROUGH 2020 ($ MILLIONS)
  • FIGURE 41 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS ANDDIAGNOSTICS BY APPLICATION SEGMENT, 2014-2020 ($ MILLIONS)
    • ASIA-PACIFIC MARKET FOR AD THERAPEUTICS BY REGION
    • TABLE 44 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
    • FIGURE 42 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
    • ASIA-PACIFIC MARKET FOR BRANDED/GENERIC AD THERAPEUTICS
    • TABLE 45 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
    • FIGURE 43 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, 2014-2020 ($ MILLIONS)
    • ASIA-PACIFIC MARKET FOR AD THERAPEUTICS BY MECHANISM OF ACTION
    • TABLE 46 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 44 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, 2014-2020 ($ MILLIONS)
      • Asia-Pacific's Market for AChEIs
      • TABLE 47 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ACETYLCHOLIN-ESTERASE INHIBITORS, THROUGH 2020 ($ MILLIONS)
      • FIGURE 45 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ACETYLCHOLIN-ESTERASE INHIBITORS, 2014-2020 ($ MILLIONS)
      • TABLE 48 ASIA-PACIFIC MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
      • FIGURE 46 ASIA-PACIFIC MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, 2014-2020 ($ MILLIONS)
      • Asia-Pacific Market for NMDA Drugs
      • TABLE 49 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH 2020 ($ MILLIONS)
      • FIGURE 47 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 ($ MILLIONS)
      • TABLE 50 ASIA-PACIFIC MARKET FOR NMDA DRUGS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
      • FIGURE 48 ASIA-PACIFIC MARKET FOR NMDA DRUGS BY COUNTRY, 2014-2020 ($ MILLIONS)
    • ASIA-PACIFIC MARKET FOR AD THERAPEUTICS BY AD STAGE
    • TABLE 51 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, THROUGH 2020 ($ MILLIONS)
    • FIGURE 49 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, 2014-2020 ($ MILLIONS)
    • ASIA-PACIFIC MARKET FOR AD DIAGNOSTICS
    • TABLE 52 ASIA-PACIFIC MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, THROUGH 2020 ($ MILLIONS)
    • FIGURE 50 ASIA-PACIFIC MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, 2014-2020 ($ MILLIONS)

CHAPTER 9 PIPELINE ANALYSIS

  • AD PIPELINE LANDSCAPE
  • AD PIPELINE: CLINICAL STAGE
  • FIGURE 51 ALZHEIMER'S DRUGS IN THE PIPELINE BY DEVELOPMENT STAGE (NUMBER OF DRUGS)
  • AD PIPELINE: TREATMENT FOCUS
  • FIGURE 52 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)
  • AD PIPELINE BY DISEASE STAGE
  • FIGURE 53 LATE PHASE II/III ALZHEIMER'S DRUGS BY DISEASE STAGE (NUMBER OF DRUGS)
  • AD PIPELINE: MECHANISM OF ACTION
  • FIGURE 54 GLOBAL CLINICAL TRIALS ON ALZHEIMER'S DRUG BY MECHANISM OF ACTION (%)
  • TABLE 53 GLOBAL ALZHEIMER'S DRUGS IN THE PIPELINE BY MECHANISM OF ACTION
  • MAJOR AB-BASED THERAPIES IN CLINICAL TRIALS
    • BIIB037/ADUCANUMAB
      • Mode of Action
      • Clinical Trial Snapshot
        • Phase I Trials
        • Phase III Trials
          • ENGAGE and EMERGE
      • Safety
      • Efficacy
      • Administration
    • SOLANEZUMAB/LY2062430
      • Mode of Action
      • Clinical Trial Snapshot
        • Phase I Trial
        • Phase II Trials
        • Phase III Trials
          • EXPEDITION 1 and 2
      • Safety
      • Efficacy
      • Administration
    • RG1450/GANTENERUMAB
      • Mode of Action
      • Clinical Trial Snapshot
        • Phase I Trials
        • Phase II/III Trials
          • Efficacy
      • Administration
    • RG7412/CRENEZUMAB
      • Mode of Action
      • Clinical Trial Snapshot
        • Phase I Trials
        • Phase II Trials
      • Safety
      • Efficacy
      • Administration
    • MK-8931/VERUBECESTAT
      • Mode of Action
      • Clinical Trial Snapshot
        • Phase I Trials
        • Phase II Trials
        • Phase III Trials
      • Safety
      • Efficacy
      • Administration
      • Benchmarking
    • CAD106
      • Mode of Action
      • Clinical Trial Snapshot
        • Phase I Trial
        • Phase II Trials
        • Phase III Trials
      • Safety
      • Efficacy
      • Administration
    • MAJOR TAU-BASED THERAPIES IN CLINICAL TRIALS
      • LMTX
      • Mode of Action
      • Clinical Trial Snapshot
        • Phase I and II Trials
        • Phase III Trials
      • Safety
      • Efficacy
      • Administration

CHAPTER 10 COMPANION DIAGNOSTICS

  • INTRODUCTION
  • FIGURE 55 FDA-APPROVED CDX TECHNOLOGIES BY INDICATED THERAPEUTIC CLASS (%)
  • FIGURE 56 FDA-APPROVED CDX-DRUG PAIRS BY MOLECULAR TARGET
  • COMPANION IMAGING DIAGNOSTICS FOR AD
  • FIGURE 57 ONGOING AB AND TAU PET IMAGING CLINICAL TRIALS (%)
  • FIGURE 58 AB AND TAU PET IMAGING TRIALS BY CLINICAL TRIAL PHASE (NUMBER OF TRIALS)
    • CIDX TECHNOLOGIES FOR AMYLOID VISUALIZATION
      • Market
      • TABLE 54 CIDX-DRUG PAIRS IN CLINICAL TRIALS
      • Pipeline
        • NAV-4694
      • Comparative Analysis of AB Tracer Technologies
        • Diagnostic Efficacy
        • Safety
        • Diagnostic Utility
    • CIDX TECHNOLOGIES FOR TAU-NFT VISUALIZATION
      • AV-1451
      • THK-5351
      • RO6958948
      • Comparative Analysis of Tau Tracers in Development
        • Diagnostic Efficacy
        • Safety
        • Diagnostic Utility
    • CIDX TECHNOLOGIES: AB VERSUS TAU IMAGING TECHNOLOGIES
    • CONCLUDING REMARKS

CHAPTER 11 COMPANY PROFILES

  • AB SCIENCE
  • ABBVIE INC.
  • AC IMMUNE SA
  • ALLERGAN PLC
  • AFFIRIS AG
  • AMARANTUS BIOSCIENCE HOLDINGS
  • ANAVEX LIFE SCIENCES
  • ASTRAZENECA
  • AVID RADIOPHARMACEUTICALS
  • AXON NEUROSCIENCE
  • AXOVANT SCIENCES
  • BIOGEN
  • BOEHRINGER INGELHEIM
  • DAIICHI SANKYO CO
  • DIAGENIC
  • EISAI
  • ELI LILLY
  • F. HOFFMANN LA ROCHE AG
  • GE HEALTHCARE
  • H. LUNDBECK A/S
  • JANSSEN PHARMACEUTICALS
  • MERCK & CO
  • NAVIDEA BIOPHARMACEUTICALS
  • NEUROTRAX CORP.
  • NOVARTIS PHARMA SERVICES AG
  • ONO PHARMACEUTICAL CO.
  • OTSUKA PHARMACEUTICALS
  • PFIZER INC
  • PIRAMAL IMAGING GMBH
  • TAURX THERAPEUTICS

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 1 PREVALENCE RATES OF ALZHEIMER'S BY REGION, 2014 (%)
  • TABLE 2 GLOBAL ALZHEIMER'S POPULATION BY AGE GROUP AND REGION, 2014 (MILLIONS)
  • TABLE 3 PHARMACOLOGICAL TREATMENT OF BPSD OF ALZHEIMER'S
  • TABLE 4 COMPUTERIZED SCREENING TESTS USED IN DETECTING COGNITIVE IMPAIRMENT
  • TABLE 5 BRAIN IMAGING TECHNOLOGIES AND APPLICATION IN THE ALZHEIMER'S CONTEXT
  • TABLE 6 DIAGNOSTIC IMAGING TRACERS APPROVED BY THE FDA
  • TABLE 7 GLOBAL MARKET SHARES OF LEADING COMPANIES IN ALZHEIMER'S THERAPEUTICS, 2020 (%)
  • TABLE 8 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 9 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 10 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 11 GLOBAL MARKET FOR GENERIC/BRANDED ALZHEIMER'S THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
  • TABLE 12 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, THROUGH 2020 ($ MILLIONS)
  • TABLE 13 GLOBAL MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, THROUGH 2020 ($ MILLIONS)
  • TABLE 14 GLOBAL MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 15 GLOBAL MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH 2020 ($ MILLIONS)
  • TABLE 16 GLOBAL MARKET FOR NMDA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 17 GLOBAL MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 18 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, THROUGH 2020 ($ MILLIONS)
  • TABLE 19 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 20 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, THROUGH 2020 ($ MILLIONS)
  • TABLE 21 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, THROUGH 2020 ($ MILLIONS)
  • TABLE 22 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
  • TABLE 23 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
  • TABLE 24 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, THROUGH 2020 ($ MILLIONS)
  • TABLE 25 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, THROUGH 2020 ($ MILLIONS)
  • TABLE 26 NORTH AMERICAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
  • TABLE 27 NORTH AMERICAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH 2020 ($ MILLIONS)
  • TABLE 28 NORTH AMERICAN MARKET FOR NMDA DRUGS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
  • TABLE 29 NORTH AMERICAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
  • TABLE 30 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, THROUGH 2020 ($ MILLIONS)
  • TABLE 31 NORTH AMERICAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, THROUGH 2020 ($ MILLIONS)
  • TABLE 32 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, THROUGH 2020 ($ MILLIONS)
  • TABLE 33 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
  • TABLE 34 EUROPEAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
  • TABLE 35 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, THROUGH 2020 ($ MILLIONS)
  • TABLE 36 EUROPEAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, THROUGH 2020 ($ MILLIONS)
  • TABLE 37 EUROPEAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
  • TABLE 38 EUROPEAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH 2020 ($ MILLIONS)
  • TABLE 39 EUROPEAN MARKET FOR NMDA DRUGS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
  • TABLE 40 EUROPEAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
  • TABLE 41 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, THROUGH 2020 ($ MILLIONS)
  • TABLE 42 EUROPEAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, THROUGH 2020 ($ MILLIONS)
  • TABLE 43 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, THROUGH 2020 ($ MILLIONS)
  • TABLE 44 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
  • TABLE 45 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
  • TABLE 46 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, THROUGH 2020 ($ MILLIONS)
  • TABLE 47 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ACETYLCHOLIN-ESTERASE INHIBITORS, THROUGH 2020 ($ MILLIONS)
  • TABLE 48 ASIA-PACIFIC MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
  • TABLE 49 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH 2020 ($ MILLIONS)
  • TABLE 50 ASIA-PACIFIC MARKET FOR NMDA DRUGS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
  • TABLE 51 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, THROUGH 2020 ($ MILLIONS)
  • TABLE 52 ASIA-PACIFIC MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, THROUGH 2020 ($ MILLIONS)
  • TABLE 53 GLOBAL ALZHEIMER'S DRUGS IN THE PIPELINE BY MECHANISM OF ACTION
  • TABLE 54 CIDX-DRUG PAIRS IN CLINICAL TRIALS

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, 2014-2020 ($ MILLIONS)
  • FIGURE 1 CHANGE IN ALZHEIMER'S POPULATION AND COST OF CARE IN THE U.S., 2015-2030 (MILLIONS/$ BILLIONS)
  • FIGURE 2 GLOBAL PREVALENCE RATES OF ALZHEIMER'S BY AGE GROUP AND REGION (%)
  • FIGURE 3 GLOBAL ALZHEIMER'S POPULATION BY AGE GROUP AND REGION, 2014 (MILLIONS)
  • FIGURE 4 GLOBAL MARKET SHARES OF LEADING COMPANIES IN ALZHEIMER'S THERAPEUTICS, 2020 (%)
  • FIGURE 5 GLOBAL MARKET SHARES OF ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, 2015 (%)
  • FIGURE 6 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, 2014-2020 ($ MILLIONS)
  • FIGURE 7 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION, 2014-2020 ($ MILLIONS)
  • FIGURE 8 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY REGION, 2014-2020 ($ MILLIONS)
  • FIGURE 9 GLOBAL MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, 2014-2020 ($ MILLIONS)
  • FIGURE 10 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, 2014-2020 ($ MILLIONS)
  • FIGURE 11 GLOBAL MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, 2014-2020 ($ MILLIONS)
  • FIGURE 12 GLOBAL MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY REGION, 2014-2020 ($ MILLIONS)
  • FIGURE 13 GLOBAL MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 ($ MILLIONS)
  • FIGURE 14 GLOBAL MARKET FOR NMDA DRUGS BY REGION, 2014-2020 ($ MILLIONS)
  • FIGURE 15 GLOBAL MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY REGION, 2014-2020 ($ MILLIONS)
  • FIGURE 16 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, 2014-2020 ($ MILLIONS)
  • FIGURE 17 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY REGION, 2014-2020 ($ MILLIONS)
  • FIGURE 18 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, 2014-2020 ($ MILLIONS)
  • FIGURE 19 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, 2014-2020 ($ MILLIONS)
  • FIGURE 20 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, 2014-2020 ($ MILLIONS)
  • FIGURE 21 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, 2014-2020 ($ MILLIONS)
  • FIGURE 22 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, 2014-2020 ($ MILLIONS)
  • FIGURE 23 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, 2014-2020 ($ MILLIONS)
  • FIGURE 24 NORTH AMERICAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS MARKET BY COUNTRY, 2014-2020 ($ MILLIONS)
  • FIGURE 25 NORTH AMERICAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 ($ MILLIONS)
  • FIGURE 26 NORTH AMERICAN MARKET FOR NMDA DRUGS BY COUNTRY, 2014-2020 ($ MILLIONS)
  • FIGURE 27 NORTH AMERICAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY COUNTRY, 2014-2020 ($ MILLIONS)
  • FIGURE 28 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE 2014-2020 ($ MILLIONS)
  • FIGURE 29 NORTH AMERICAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, 2014-2020 ($ MILLIONS)
  • FIGURE 30 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, 2014-2020 ($ MILLIONS)
  • FIGURE 31 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, 2014-2020 ($ MILLIONS)
  • FIGURE 32 EUROPEAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, 2014-2020 ($ MILLIONS)
  • FIGURE 33 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, 2014-2020 ($ MILLIONS)
  • FIGURE 34 EUROPEAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, 2014-2020 ($ MILLIONS)
  • FIGURE 35 EUROPEAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, 2014-2020 ($ MILLIONS)
  • FIGURE 36 EUROPEAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 ($ MILLIONS)
  • FIGURE 37 EUROPEAN MARKET FOR NMDA DRUGS BY COUNTRY, 2014-2020 ($ MILLIONS)
  • FIGURE 38 EUROPEAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
  • FIGURE 39 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, 2014-2020 ($ MILLIONS)
  • FIGURE 40 EUROPEAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, 2014-2020 ($ MILLIONS)
  • FIGURE 41 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, 2014-2020 ($ MILLIONS)
  • FIGURE 42 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 ($ MILLIONS)
  • FIGURE 43 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, 2014-2020 ($ MILLIONS)
  • FIGURE 44 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, 2014-2020 ($ MILLIONS)
  • FIGURE 45 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ACETYLCHOLIN-ESTERASE INHIBITORS, 2014-2020 ($ MILLIONS)
  • FIGURE 46 ASIA-PACIFIC MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, 2014-2020 ($ MILLIONS)
  • FIGURE 47 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 ($ MILLIONS)
  • FIGURE 48 ASIA-PACIFIC MARKET FOR NMDA DRUGS BY COUNTRY, 2014-2020 ($ MILLIONS)
  • FIGURE 49 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, 2014-2020 ($ MILLIONS)
  • FIGURE 50 ASIA-PACIFIC MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, 2014-2020 ($ MILLIONS)
  • FIGURE 51 ALZHEIMER'S DRUGS IN THE PIPELINE BY DEVELOPMENT STAGE (NUMBER OF DRUGS)
  • FIGURE 52 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)
  • FIGURE 53 LATE PHASE II/III ALZHEIMER'S DRUGS BY DISEASE STAGE (NUMBER OF DRUGS)
  • FIGURE 54 GLOBAL CLINICAL TRIALS ON ALZHEIMER'S DRUG BY MECHANISM OF ACTION (%)
  • FIGURE 55 FDA-APPROVED CDX TECHNOLOGIES BY INDICATED THERAPEUTIC CLASS (%)
  • FIGURE 56 FDA-APPROVED CDX-DRUG PAIRS BY MOLECULAR TARGET
  • FIGURE 57 ONGOING AB AND TAU PET IMAGING CLINICAL TRIALS (%)
  • FIGURE 58 AB AND TAU PET IMAGING TRIALS BY CLINICAL TRIAL PHASE (NUMBER OF TRIALS)
Back to Top